ImmunoPrecise Antibodies (NASDAQ:IPA) is a global biotechnology company specializing in the discovery, development and optimization of antibody-based therapeutics and research reagents. The company leverages a range of proprietary platforms—including mouse, rabbit, llama and human immune libraries, single B-cell screening, hybridoma technology and next-generation sequencing—to deliver custom monoclonal and polyclonal antibodies. Services extend from target validation through lead selection, with capabilities in epitope mapping, affinity maturation and immunoassay development.
Established in 2007 and headquartered in Victoria, British Columbia, ImmunoPrecise has expanded its footprint across North America, Europe and Asia. In addition to its Canadian operations, the company maintains research and development centers in Cambridge, UK, Seattle and Tianjin, China. This geographic diversity enables collaborations with pharmaceutical, biotechnology and academic clients seeking tailored antibody solutions for oncology, immunology, infectious disease and rare disorders.
ImmunoPrecise’s integrated service model supports programs at every stage of the discovery value chain. Early discovery workflows include antigen generation, in vivo immunization protocols and in vitro library screening, while later-stage services encompass cell line development, cell banking and process development for GMP manufacturing. The company’s continuous investment in platform enhancements—such as high-throughput sequencing and advanced bioinformatics—aims to accelerate timelines and improve candidate quality for challenging targets.
Under the leadership of Chief Executive Officer Dr. Daniel Kikly, ImmunoPrecise has pursued strategic partnerships and acquisitions to broaden its technology stack and market reach. The management team combines experience in monoclonal antibody research, diagnostics and biologics manufacturing, positioning the company to address evolving needs in drug discovery and translational research. As demand for bespoke antibody reagents grows, ImmunoPrecise seeks to capitalize on its established platforms and global network to support clients’ pipeline advancement and entry into clinical development.
